Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cullinan Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CGEM
Nasdaq
8731
https://www.cullinanoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cullinan Oncology Inc
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
- Apr 16th, 2024 7:32 pm
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Apr 16th, 2024 11:00 am
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Apr 16th, 2024 10:59 am
Cullinan changes name, pivots to autoimmune disease
- Apr 16th, 2024 8:48 am
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 16th, 2024 9:31 am
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
- Mar 15th, 2024 11:34 am
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 14th, 2024 11:00 am
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Mar 1st, 2024 12:00 pm
Cullinan Oncology to Participate in Upcoming Investor Conferences
- Feb 27th, 2024 1:00 pm
13 Best Booming Stocks to Buy Right Now
- Feb 21st, 2024 2:21 pm
Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc
- Feb 3rd, 2024 4:01 am
Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares
- Jan 25th, 2024 12:02 am
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 18th, 2023 9:53 pm
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
- Dec 14th, 2023 9:30 pm
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 8th, 2023 12:00 pm
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
- Nov 3rd, 2023 4:01 pm
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Aug 10th, 2023 11:00 am
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Aug 9th, 2023 11:00 am
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Aug 3rd, 2023 8:15 pm
Why Shares of Cullinan Oncology Jumped This Week
- Jun 9th, 2023 8:07 pm
Scroll